ETTX Entasis Therapeutics Holdings Inc

Entasis Therapeutics (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced that Manos Perros, President and Chief Executive Officer, will present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference in New York, NY.

Event: BMO Capital Markets 2018 Prescriptions for Success Healthcare ConferenceDate: December 12, 2018 at 2:00 PM ETLocation: Mandarin Oriental Hotel, New York, NY

A live webcast of the presentation can be accessed under "Investors & Media" in the “News & Events” section of the Company's website at www.entasistx.com.

About EntasisEntasis Therapeutics is developing a portfolio of innovative product candidates to treat serious Gram-negative multi-drug resistant bacterial infections. Entasis’ anti-infective discovery platform has produced a pipeline of meaningfully differentiated programs which target serious bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae), ETX0282CPDP (targeting Enterobacteriaceae infections), and non-β-lactam PBP inhibitors or NBPs (targeting Gram-negative infections). www.entasistx.com

Company Contact                                                     Kyle Dow  Entasis Therapeutics    (781) 810-0114        kyle.dow@entasistx.com   

Investor ContactChris BrinzeyWestwicke Partners(339) 970-2843Chris.brinzey@westwicke.com

Media ContactKari Watson or Stefanie TuckMacDougall Biomedical Communications(781) 235-3060kwatson@macbiocom.com or stuck@macbiocom.com